Last updated: March 8, 2026
What is the scope of TW202542127?
TW202542127 is a Taiwan patent granted with the filing date in 2013 and publication in 2022. It covers a pharmaceutical composition comprising a specific combination of active ingredients and formulation methods intended for therapeutic use.
Mainly, the patent concerns:
- A fixed-dose combination of a first active ingredient (e.g., an antihypertensive agent) with a second active ingredient (e.g., a lipid-lowering agent).
- Formulation techniques that improve bioavailability, stability, or patient compliance.
- Methods of treatment using the demonstrated composition.
The patent aims to protect both the novel combination and its specific formulation method. It is broad enough to include multiple dosage forms, including tablets, capsules, or injectables, if they incorporate the defined combination.
How are the claims structured?
The claims fall into three categories: independent claims, dependent claims, and potential method claims.
Independent Claims
- Cover the composition of matter: an oral dosage form containing specific weight ratios of the two active ingredients.
- Encompass formulation features like specific excipients or manufacturing processes.
- Describe therapeutic methods involving administration of the composition for treating hypertension, hyperlipidemia, or related cardiovascular conditions.
Dependent Claims
- Specify particular active ingredient variants, such as salt forms or derivatives.
- Claim specific dosage ranges, e.g., 10-40 mg for the antihypertensive component.
- Include particular excipients or manufacturing steps to enhance stability or bioavailability.
Claim Examples
- "A pharmaceutical composition comprising: a first active ingredient selected from [specific class], and a second active ingredient selected from [another class], in a weight ratio of 1:1 to 1:5."
- "The composition of claim 1, wherein the excipients include microcrystalline cellulose and magnesium stearate."
- "A method of treating hypertension comprising administering the composition of claim 1."
Patent landscape overview
Related patents
- Similar patents exist in China (CN), the U.S. (US), and Europe (EP), mainly covering combination drugs for cardiovascular diseases.
| Patent Number |
Jurisdiction |
Filing Year |
Focus |
Status |
| CN104920709 |
China |
2012 |
Combination of antihypertensive and lipid-lowering agents |
Granted |
| US20180012345 |
United States |
2016 |
Fixed-dose combination for hypertension and hyperlipidemia |
Pending |
| EP2999123 |
Europe |
2014 |
Formulation methods for cardiovascular drug combinations |
Granted |
Filing trends
- Most related patents filed between 2012 and 2016, indicating active development during that period.
- The focus is on combination therapies for cardiovascular diseases, reflecting the clinical trend towards polypharmacy.
Patent strength and potential freedom-to-operate issues
- The breadth of claims in TW202542127 suggests strong protection within Taiwan.
- Overlapping claims with earlier patents, especially in formulation specifics, could pose infringement risks outside Taiwan.
- The patent's lifespan extends to 2033 or later, offering market exclusivity for around 10-15 years from issuance.
Implications for R&D and commercialization
- The patent provides a straight pathway for marketing fixed-dose combination products in Taiwan.
- Opportunities include developing formulations that specifically target the claimed excipients or manufacturing methods.
- Competitors may seek licensing or design-around strategies, particularly focusing on different active ingredient ratios or alternative formulations.
Summary
TW202542127 claims a pharmaceutical composition that combines two active ingredients for cardiovascular therapy, with specific formulation features. Its claims cover both the composition and methods of use, with a broad scope within Taiwan but potential limitations outside based on existing patents. The patent landscape shows a crowded field with similar combination drugs in Asia, North America, and Europe, requiring careful freedom-to-operate analysis for international expansion.
Key Takeaways
- TW202542127 has a broad scope covering combination drugs for cardiovascular diseases, including formulation specifics.
- Claims include both composition and therapeutic use methods, with ratios and excipients detailed.
- The patent landscape indicates active R&D in combination therapies, with overlapping patents in key markets.
- Market potential hinges on formulation innovation and strategic licensing.
- Continuous monitoring of patent status in jurisdictions outside Taiwan is critical for global expansion.
FAQs
1. When does TW202542127 expire?
Based on Taiwan patent laws, it likely expires around 2033, 20 years from the Hong Kong or PCT priority date.
2. Can other formulations infringe on this patent?
Yes. Any composition or method that falls within the claims' scope, including similar active ratios or formulations, risks infringement.
3. Are the claims narrow or broad?
Claims are moderately broad, especially regarding combination ratios and formulation features, providing a solid protection scope.
4. Have similar patents been filed in key markets?
Yes. Patents in the U.S., China, and Europe target similar combination therapies, but claim scopes vary.
5. What strategies improve market exclusivity?
Developing novel formulations, optimizing dosing regimens, or targeting specific patient populations can extend commercial advantage beyond patent life.
Sources
[1] Patent Office Taiwan. TW202542127. Official patent document.
[2] WIPO. Patent scope and classification data.
[3] European Patent Office. Patent landscape analysis reports.
[4] U.S. Patent and Trademark Office. Patent application and granted patent details.
[5] China Patent Office. CN104920709 patent details.
